Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EMC
Global X Emerging Markets Great Consumer ETF
$37.05
+0.3%
$33.20
$27.39
$37.56
$65.58M0.8213,966 shs5,856 shs
IMV Inc. stock logo
IMV
IMV
C$0.00
C$0.62
C$15.90
C$13.12M1.5256,822 shs15,761 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.57
+1.4%
$0.58
$0.48
$3.09
$3.61M1.6134,778 shs11,813 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.10
+5.3%
C$0.11
C$0.04
C$0.30
C$31.62M0.71830831,637 shs6,000 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EMC
Global X Emerging Markets Great Consumer ETF
+0.30%+0.95%+9.39%+9.88%+31.71%
IMV Inc. stock logo
IMV
IMV
0.00%0.00%0.00%0.00%0.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
+1.44%-11.30%+8.15%-3.05%-16.81%
Resverlogix Corp. stock logo
RVX
Resverlogix
+5.26%0.00%-4.76%+5.26%+150.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EMC
Global X Emerging Markets Great Consumer ETF
$37.05
+0.3%
$33.20
$27.39
$37.56
$65.58M0.8213,966 shs5,856 shs
IMV Inc. stock logo
IMV
IMV
C$0.00
C$0.62
C$15.90
C$13.12M1.5256,822 shs15,761 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.57
+1.4%
$0.58
$0.48
$3.09
$3.61M1.6134,778 shs11,813 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.10
+5.3%
C$0.11
C$0.04
C$0.30
C$31.62M0.71830831,637 shs6,000 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EMC
Global X Emerging Markets Great Consumer ETF
+0.30%+0.95%+9.39%+9.88%+31.71%
IMV Inc. stock logo
IMV
IMV
0.00%0.00%0.00%0.00%0.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
+1.44%-11.30%+8.15%-3.05%-16.81%
Resverlogix Corp. stock logo
RVX
Resverlogix
+5.26%0.00%-4.76%+5.26%+150.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EMC
Global X Emerging Markets Great Consumer ETF
2.74
Moderate Buy$37.05N/A
IMV Inc. stock logo
IMV
IMV
0.00
N/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00
N/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EMC
Global X Emerging Markets Great Consumer ETF
N/AN/AN/AN/AN/AN/A
IMV Inc. stock logo
IMV
IMV
C$23K0.00N/A1.61C($0.69) per share0.00
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.10M3.33N/AN/A$0.47 per share1.22
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.31) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EMC
Global X Emerging Markets Great Consumer ETF
N/A$1.0734.63N/AN/AN/AN/AN/AN/A
IMV Inc. stock logo
IMV
IMV
-C$37.99M-C$6.11N/AN/AN/AN/A-508.58%-61.78%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$10.35M-$3.89N/AN/AN/AN/A-193.02%-124.09%N/A
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$2.81M-C$0.03N/AN/AN/AN/A8.40%-34.90%N/A

Latest RVX, EMC, MTNB, and IMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A-$0.30N/A-$0.30N/AN/A
3/31/2026Q4 2025
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A-$0.26N/A-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
EMC
Global X Emerging Markets Great Consumer ETF
$0.240.65%N/A22.43%N/A
IMV Inc. stock logo
IMV
IMV
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A7.02%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EMC
Global X Emerging Markets Great Consumer ETF
N/AN/AN/A
IMV Inc. stock logo
IMV
IMV
1,231.01
2.93
2.32
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
1.32
2.79
Resverlogix Corp. stock logo
RVX
Resverlogix
-81.94
0.04
0.04

Institutional Ownership

CompanyInstitutional Ownership
EMC
Global X Emerging Markets Great Consumer ETF
79.86%
IMV Inc. stock logo
IMV
IMV
20.37%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Resverlogix Corp. stock logo
RVX
Resverlogix
0.01%

Insider Ownership

CompanyInsider Ownership
EMC
Global X Emerging Markets Great Consumer ETF
0.40%
IMV Inc. stock logo
IMV
IMV
0.41%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
Resverlogix Corp. stock logo
RVX
Resverlogix
42.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
EMC
Global X Emerging Markets Great Consumer ETF
N/A1.77 millionN/ANot Optionable
IMV Inc. stock logo
IMV
IMV
2011.71 millionN/ANot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
306.41 million6.11 millionN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
19316.17 millionN/ANot Optionable

Recent News About These Companies

Resverlogix Corp. Announces Issuance of MCTO by ASC
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Resverlogix Appoints Bradley Glass to Board of Directors

Media Sentiment Over Time

Global X Emerging Markets Great Consumer ETF NYSEARCA:EMC

$37.05 +0.11 (+0.30%)
As of 05/14/2026 04:10 PM Eastern

The Global X Emerging Markets Great Consumer ETF (EMC) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that invests in companies across multiple sectors that are positioned to benefit from the increasing consumption and growing purchasing power of consumers from the emerging markets. EMC was launched on Sep 24, 2010 and is managed by Global X.

IMV stock logo

IMV TSE:IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Matinas Biopharma stock logo

Matinas Biopharma NYSEAMERICAN:MTNB

$0.57 +0.01 (+1.44%)
As of 05/14/2026 04:10 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Resverlogix stock logo

Resverlogix TSE:RVX

C$0.10 +0.01 (+5.26%)
As of 05/14/2026 03:36 PM Eastern

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.